{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:19:26Z","timestamp":1772050766894,"version":"3.50.1"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Several studies have demonstrated the occurrence of secondary tumors as a rare but significant complication of chimeric antigen receptor T (CAR-T) cell therapy, underscoring the need for a detailed investigation. Given the limited variety of secondary tumor types reported to date, a comprehensive characterization of the various secondary tumors arising after CAR-T therapy is essential to understand the associated risks and to define the role of the immune microenvironment in malignant transformation. This study aims to characterize the immune microenvironment of a newly identified secondary tumor post-CAR-T therapy, to clarify its pathogenesis and potential therapeutic targets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this study, the bone marrow (BM) samples were collected by aspiration from the primary and secondary tumors before and after CD19 CAR-T treatment. The CD45<jats:sup>+<\/jats:sup> BM cells were enriched with human CD45 microbeads. The CD45<jats:sup>+<\/jats:sup> cells were then sent for 10\u00d7 genomics single-cell RNA sequencing (scRNA-seq) to identify cell populations. The Cell Ranger pipeline and CellChat were used for detailed analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In this study, a rare type of secondary chronic myelomonocytic leukemia (CMML) were reported in a patient with diffuse large B-cell lymphoma (DLBCL) who had previously received CD19 CAR-T therapy. The scRNA-seq analysis revealed increased inflammatory cytokines, chemokines, and an immunosuppressive state of monocytes\/macrophages, which may impair cytotoxic activity in both T and natural killer (NK) cells in secondary CMML before treatment. In contrast, their cytotoxicity was restored in secondary CMML after treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This finding delineates a previously unrecognized type of secondary tumor, CMML, after CAR-T therapy and provide a framework for defining the immune microenvironment of secondary tumor occurrence after CAR-T therapy. In addition, the results provide a rationale for targeting macrophages to improve treatment strategies for CMML treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003690","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:00:09Z","timestamp":1751954409000},"page":"1866-1881","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large B-cell lymphoma with CD19 CAR-T failure by single-cell RNA-sequencing"],"prefix":"10.1097","volume":"138","author":[{"given":"Xudong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binglei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Shi","sequence":"additional","affiliation":[{"name":"BGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan 450052, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuke","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Public Health, Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilei","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhou","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linping","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"},{"name":"Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 450007, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41375-023-01890-4","article-title":"What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?","volume":"37","author":"Zhao","year":"2023","journal-title":"Leukemia"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.xcrm.2024.101585","article-title":"Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia","volume":"5","author":"Montalban-Bravo","year":"2024","journal-title":"Cell Rep Med"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.2021015173","article-title":"Role of allogeneic transplantation in chronic myelomonocytic leukemia: An international collaborative analysis","volume":"140","author":"Robin","year":"2022","journal-title":"Blood"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.2024025648","article-title":"Perspectives on drug development in chronic myelomonocytic leukemia: Changing the paradigm","volume":"144","author":"Hunter","year":"2024","journal-title":"Blood"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: A retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/ajh.27492","article-title":"PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","article-title":"Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: Case series and review of literature","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","article-title":"Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy","volume":"8","author":"Melody","year":"2024","journal-title":"Blood Adv"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after Cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-T-cell therapy: A review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2643-3230.BCD-21-0217","article-title":"Progenitor hierarchy of chronic myelomonocytic leukemia identifies inflammatory monocytic-biased trajectory linked to worse outcomes","volume":"3","author":"Ferrall-Fairbanks","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.ebiom.2020.102904","article-title":"Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome","volume":"58","author":"Wiseman","year":"2020","journal-title":"EBioMedicine"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood-2021-151340","article-title":"Single-cell RNA sequencing analysis reveals mechanisms of initiation and progression in chronic myelomonocytic leukemia","volume":"138","author":"Montalban-Bravo","year":"2021","journal-title":"Blood"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2019000430","article-title":"Identification and transcriptome analysis of erythroblastic island macrophages","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"R21-20250805","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood.2020007401","article-title":"Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12967-021-03214-5","article-title":"GM-CSF impairs erythropoiesis by disrupting erythroblastic island formation via macrophages","volume":"20","author":"Cao","year":"2022","journal-title":"J Transl Med"},{"key":"R23-20250805","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"R24-20250805","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41421-022-00417-y","article-title":"Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq","volume":"8","author":"You","year":"2022","journal-title":"Cell Discovery"},{"key":"R25-20250805","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"R26-20250805","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"key":"R27-20250805","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","article-title":"Activity of venetoclax-based therapy in chronic myelomonocytic leukemia","volume":"35","author":"Montalban-Bravo","year":"2021","journal-title":"Leukemia"},{"key":"R28-20250805","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3109\/10428194.2016.1138295","article-title":"A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza\u00ae) in patients with chronic myelomonocytic leukemia","volume":"57","author":"Tantravahi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R29-20250805","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1096\/fj.05-5460rev","article-title":"Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis","volume":"20","author":"Rege","year":"2006","journal-title":"FASEB J"},{"key":"R30-20250805","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1359-6101(02)00006-0","article-title":"On the TRAIL to apoptosis","volume":"13","author":"Baetu","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"R31-20250805","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.cdd.4400827","article-title":"APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis","volume":"8","author":"Roth","year":"2001","journal-title":"Cell Death Differ"},{"key":"R32-20250805","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"R33-20250805","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0008-8749(03)00060-1","article-title":"Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells","volume":"221","author":"Sartorius","year":"2003","journal-title":"Cell Immunol"},{"key":"R34-20250805","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2249.2010.04210.x","article-title":"CD23\/Fc\u03b5RII: Molecular multi-tasking","volume":"162","author":"Acharya","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"R35-20250805","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"R36-20250805","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: Analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"R37-20250805","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second Primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R38-20250805","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"R39-20250805","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"R40-20250805","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"R41-20250805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141228","article-title":"MDS\/CMML with TET2 or IDH mutation are associated with systemic inflammatory and autoimmune diseases (SIAD) and T cell dysregulation","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"R42-20250805","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2013.337","article-title":"The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","volume":"28","author":"Solary","year":"2014","journal-title":"Leukemia"},{"key":"R43-20250805","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","article-title":"Mutational landscape of chronic myelomonocytic leukemia in Chinese patients","volume":"11","author":"Nie","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R44-20250805","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"R45-20250805","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"R46-20250805","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/bloodadvances.2019000585","article-title":"The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations","volume":"3","author":"Franzini","year":"2019","journal-title":"Blood Adv"},{"key":"R47-20250805","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"key":"R48-20250805","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"R49-20250805","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"R50-20250805","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3070","article-title":"Monocyte recruitment during infection and inflammation","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"R51-20250805","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2017.01.004","article-title":"Regulation of Inflammation- and Infection-Driven Hematopoiesis","volume":"38","author":"Boettcher","year":"2017","journal-title":"Trends Immunol"},{"key":"R52-20250805","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"R53-20250805","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"R54-20250805","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-023-05284-5","article-title":"Contributions of bone marrow monocytes\/macrophages in myeloproliferative neoplasms with JAK2V617F mutation","volume":"102","author":"Fan","year":"2023","journal-title":"Ann Hematol"},{"key":"R55-20250805","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jamaneurol.2017.0357","article-title":"Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes","volume":"74","author":"Zhao","year":"2017","journal-title":"JAMA Neurol"},{"key":"R56-20250805","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2021-152694","article-title":"Monocytes from patients with polycythemia vera express molecules related to stress erythropoiesis and have increased erythrocyte phagocytosis","volume":"138","author":"Borges","year":"2021","journal-title":"Blood"},{"key":"R57-20250805","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1189\/jlb.5RU0116-016R","article-title":"The role of macrophages in obesity-driven chronic liver disease","volume":"99","author":"Devisscher","year":"2016","journal-title":"J Leukoc Biol"},{"key":"R58-20250805","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(03)00174-2","article-title":"Blood monocytes monsist of two principal subsets with distinct migratory properties","volume":"19","author":"Geissmann","year":"2003","journal-title":"Immunity"},{"key":"R59-20250805","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","article-title":"blood monocytes: Development, heterogeneity, and relationship with dendritic cells","volume":"27","author":"Auffray","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"R60-20250805","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cellimm.2014.07.007","article-title":"Inflammatory monocyte effector mechanisms","volume":"291","author":"Lauvau","year":"2014","journal-title":"Cell Immunol"},{"key":"R61-20250805","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"key":"R62-20250805","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","article-title":"Targeting macrophages in hematological malignancies: Recent advances and future directions","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R63-20250805","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.drup.2024.101068","article-title":"Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy","volume":"74","author":"Zhang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"R64-20250805","doi-asserted-by":"crossref","first-page":"101329","DOI":"10.1016\/j.xcrm.2023.101329","article-title":"NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy","volume":"4","author":"Hurtado-Navarro","year":"2023","journal-title":"Cell Rep Med"},{"key":"R65-20250805","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","article-title":"Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML","volume":"33","author":"Niyongere","year":"2019","journal-title":"Leukemia"},{"key":"R66-20250805","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1006\/smim.2001.0345","article-title":"Chemokines in rapid leukocyte adhesion triggering and migration","volume":"14","author":"Johnston","year":"2002","journal-title":"Semin Immunol"},{"key":"R67-20250805","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.immuni.2023.08.002","article-title":"Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation","volume":"56","author":"Pekayvaz","year":"2023","journal-title":"Immunity"},{"key":"R68-20250805","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1038\/sj.onc.1208797","article-title":"Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer","volume":"24","author":"Einav","year":"2005","journal-title":"Oncogene"},{"key":"R69-20250805","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.2174\/0929867328666210617105209","article-title":"Roles of Interferon Induced Protein with Tetratricopeptide Repeats (IFIT) Family in Cancer","volume":"28","author":"Tan","year":"2021","journal-title":"Curr Med Chem"},{"key":"R70-20250805","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2567.2000.00997.x","article-title":"Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes","volume":"100","author":"Mathy","year":"2000","journal-title":"Immunology"},{"key":"R71-20250805","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140644","article-title":"Initial results of a phase I\/II study of venetoclax in combination with azacitidine in treatment-naive and relapsed\/refractory high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)","volume":"136","author":"Morita","year":"2020","journal-title":"Blood"},{"key":"R72-20250805","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1074-7613(95)90164-7","article-title":"CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18","volume":"3","author":"Lecoanet-Henchoz","year":"1995","journal-title":"Immunity"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T04:05:23Z","timestamp":1754366723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":72,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003690","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"2024-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}